Online inquiry

IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9566MR)

This product GTTS-WQ9566MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&MET gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001346897.2; NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 4233
UniProt ID Q504U8; P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9566MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8938MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ1890MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ14617MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ2409MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ15115MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ108MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ7103MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ8905MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IGE25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW